MX2018009368A - Biomarcadores para copanlisib. - Google Patents

Biomarcadores para copanlisib.

Info

Publication number
MX2018009368A
MX2018009368A MX2018009368A MX2018009368A MX2018009368A MX 2018009368 A MX2018009368 A MX 2018009368A MX 2018009368 A MX2018009368 A MX 2018009368A MX 2018009368 A MX2018009368 A MX 2018009368A MX 2018009368 A MX2018009368 A MX 2018009368A
Authority
MX
Mexico
Prior art keywords
biomarkers
patients
copanlisib
response
nhls
Prior art date
Application number
MX2018009368A
Other languages
English (en)
Inventor
Liu Li
Pena Carol
Cheng Jie
Köchert Karl
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2018009368A publication Critical patent/MX2018009368A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona biomarcadores que se basan en los perfiles de expresión génica los cuales pueden discriminar entre pacientes quienes responden al tratamiento con copanlisib y/o con supervivencia más larga libre de progresión y pacientes quienes no responden al tratamiento con copanlisib y/o con supervivencia más corta libre de progresión en linfoma que incluye LNH indolente y agresivo y LLC. La presente invención se refiere al uso de genes de los procesos del BCR, PI3K, NFkB, IL6, inflamación y estromales como biomarcadores predictivos de diversos cánceres humanos que incluyen, entre otros, los LNH.
MX2018009368A 2016-02-01 2017-01-30 Biomarcadores para copanlisib. MX2018009368A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662289713P 2016-02-01 2016-02-01
US201662376017P 2016-08-17 2016-08-17
PCT/EP2017/051903 WO2017134000A1 (en) 2016-02-01 2017-01-30 Copanlisib biomarkers

Publications (1)

Publication Number Publication Date
MX2018009368A true MX2018009368A (es) 2018-09-05

Family

ID=57984901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009368A MX2018009368A (es) 2016-02-01 2017-01-30 Biomarcadores para copanlisib.

Country Status (16)

Country Link
US (1) US20190038632A1 (es)
EP (1) EP3411497A1 (es)
JP (1) JP2019511204A (es)
KR (1) KR20180101603A (es)
CN (1) CN108884496A (es)
AU (1) AU2017214230A1 (es)
BR (1) BR112018015782A2 (es)
CA (1) CA3012890A1 (es)
CL (1) CL2018002069A1 (es)
MA (1) MA43957A (es)
MX (1) MX2018009368A (es)
PH (1) PH12018501623A1 (es)
SG (2) SG11201806274SA (es)
SV (1) SV2018005730A (es)
TN (1) TN2018000271A1 (es)
WO (1) WO2017134000A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
US10406162B2 (en) 2015-03-09 2019-09-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations
CA3016584A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
CU24607B1 (es) * 2017-09-08 2022-06-06 Bayer Consumer Care Ag Sólido estable, liofilizado, que contiene copanlisib, útil para dilución y aplicaciones terapéuticas
WO2020092860A1 (en) * 2018-11-01 2020-05-07 The Jackson Laboratory Gastric cancer treatments
EP4231872A1 (en) 2020-10-21 2023-08-30 Black Jet Innovations, Inc. Mobile device grip and stand

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JP6368353B2 (ja) * 2013-04-08 2018-08-01 バイエル ファーマ アクチエンゲゼルシャフト 置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類のリンパ腫治療への使用
EP3543355B1 (en) * 2013-06-20 2020-12-23 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic efficacy of p13k/akt/mtor inhibitor on basis of phlda1 or pik3c2b expression
KR20160132067A (ko) * 2014-03-11 2016-11-16 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 암 공격성, 예후 및 치료에 대한 반응성의 결정
WO2015160986A2 (en) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法

Also Published As

Publication number Publication date
TN2018000271A1 (en) 2020-01-16
JP2019511204A (ja) 2019-04-25
BR112018015782A2 (pt) 2019-01-02
CN108884496A (zh) 2018-11-23
US20190038632A1 (en) 2019-02-07
CL2018002069A1 (es) 2018-11-16
MA43957A (fr) 2018-12-12
SG11201806274SA (en) 2018-08-30
AU2017214230A1 (en) 2018-08-09
SG10202007262PA (en) 2020-09-29
SV2018005730A (es) 2018-12-05
PH12018501623A1 (en) 2019-06-03
EP3411497A1 (en) 2018-12-12
WO2017134000A1 (en) 2017-08-10
KR20180101603A (ko) 2018-09-12
CA3012890A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
PH12018501623A1 (en) Copanlisib biomarkers
PH12018501622A1 (en) Copanlisib biomarkers
CY1125588T1 (el) Θεραπευτικοι συνδυασμοι ενος αναστολεα βτκ και ενος αναστολεα bcl-2
EA202191009A1 (ru) Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k
MX2022001105A (es) Anticuerpos anti tigit.
TR201901939T4 (tr) Antisens nükleik asit.
MX2017006785A (es) Metodos y composiciones para radioetiquetado con 18f de productos biologicos.
WO2014144121A3 (en) Classification and actionability indices for lung cancer
MX2017006864A (es) Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
BR112016026730A2 (pt) métodos de caracterização e tratamento de leucemia mieloide aguda
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
CL2017001487A1 (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr.
MX2018004542A (es) Neoepítopos virales y sus usos.
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
IN2014DN08312A (es)
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
MX2017007676A (es) Nuevos compuestos.
TWD195924S (zh) 寶石
NZ765619A (en) Genes and gene signatures for diagnosis and treatment of melanoma
CL2015003771A1 (es) Método ex vivo pronóstico y predictivo de respuesta de un cáncer al tratamiento con un agente antitumoral
AR104791A1 (es) Métodos terapéuticos y diagnósticos para el cáncer
PL408373A1 (pl) Startery, zestaw starterów, sondy molekularne, zestaw sond molekularnych, zestaw starterów i sond oraz zastosowanie starterów i sond w technice dyskryminacji alleli do wykrywania mutacji w genie BRCA1 i diagnozowania raka piersi
UA111914U (uk) Спосіб прогнозування метастазування у хворих на рак молочної залози